Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2023)
15 slides from Nova Eye Medical's shareholder meeting presentation, Nov 23, 2023
Slide 1: Addressing the two leading causes of blindness in the developed world
Addressing the two leading causes of blindness in the developed world Nova Eye Medical Limited (ASX:EYE) Managing Director Presentation to Annual General Meeting November 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Nova Eye is addressing large unmet needs
Nova Eye is addressing large unmet needs Glaucoma Opportunity AMD Opportunity • 156 million (1) people with glaucoma • 200million (2) people with Age Related Macular worldwide US$6.1m(1) annual expenditure on Degeneration (AMD) worldwide with only 29 million topical drugs US$607m (1) annual expendit
Slide 4: RECAP
RECAP Strong Sales in FY23 and strong growth in USA during FY24 FY 23 Record MACs sudden Despite temporary global sales US sales for decision to re- interruption, we see 4 months ended classify canaloplasty a strong future for US$11.3m 31 October 2023 as an investigational iTrack and a return for th
Slide 5: Proposed USA Medicare Changes
Proposed USA Medicare Changes Local coverage determination (LCD) proposed changes for There are 7 MACs in the USA and Medicare reimbursement of (MIGS) in the USA, affecting six the remaining 2 have so far not companies directly, have been proposed by 5 Medicare participated and new changes Administr
Slide 6: Molteno3 Glaucoma Drainage Device: 30+ years, 0.4mm
Implanted in thousands of patients worldwide for more than 30 years, the Molteno3® Glaucoma Drainage Device has been clinically 30+ years validated to deliver consistent, long-term of surgical use reduction in intraocular pressure (IOP) in cases of severe or complex glaucoma. Indication Glaucoma Dra
Slide 7: Overcoming the USA Reimbursement Challenges
Overcoming the USA Reimbursement Challenges • The changes by the MACs, if implemented are expected to cause a temporary reduction in sales growth in the USA in the coming months. • Nova Eye has invested in an expansive IP portfolio that provides us with options to release of new devices and to expan
Slide 8: Nova Eye Current Glaucoma Product Portfolio
Nova Eye Current Glaucoma Product Portfolio iTrack Advance iTrack Molteno 3 iLumin nova-eye.com | 8
Slide 9: Sales update for the four months to 31 October 2023
Sales update for the four months to 31 October 2023 US$ millions (unaudited sales) 4 months ended 4 months ended Growth on PCP 31 October 2022 31 October 2023 USA 1.92 3.34 74% (1) Germany and Europe 1.07 0.81 -24% (2) Global excluding China 2.99 4.15 39% China 0.78 - Timing (3) Global including Chi
Slide 10: Growth Opportunities Outside of the USA
Growth Opportunities Outside of the USA Markets outside of the USA continue to offer potential for Nova Eye’s portfolio of proprietary products. Nova Eye Medical secured several important registrations in key strategic markets outside of the USA during the period. Registrations for iTrack Advance in
Slide 11: AMD affects 200m people worldwide causing blindness
AMD affects 200m people worldwide causing blindness Intermediate stage disease – AlphaRET Preventing onset of Late stage AMD 2RT Treatment Wet Dry Intermediate AMD (CNV) AMD (GA) Intermediate AMD Choroidal Neovascularization Geographic Atrophy AMD 55 million54 million 15 million 14 million people wo
Slide 12: 2RT for Intervention in AMD Progression
2RT® for Intervention in AMD Progression Intervention schematic based on LEAD* Clinical Trial demonstrated 77% reduction in the rate of progression in patients without reticular pseudodrusen (RPD) at enrolment. 24% of the study population had RPD at enrolment New Protocol to exclude RPD patients fro
Slide 13: Current regulatory approvals for 2RT
Current regulatory approvals for 2RT® • Europe and Mutual Recognition Jurisdictions (including Switzerland, UK, Australia, NZ) where 2RT is approved for the treatment of patients with early AMD where it is approved for bilateral improvement in macular appearance and function. • Europe and Mutual Rec
Slide 14: Nova Eye Group Outlook
Nova Eye Group Outlook Sales of new iTrack™ Advance in the USA are currently running above plan but recent proposed changes to reimbursement coverage for canaloplasty procedures is expected to negatively impact sales in the coming months In the medium to longer term USA sales growth is expected to r
Slide 15: Contacts
Tom Spurling Mark Flynn Kate Hunt Managing Director Investor Relations Chief Commercial Officer M: +61 417 818 658 M: +61 416 068 733 M: +61 404 080 679 E: tspurling@nova-eye.com E: mflynn@nova-eye.com E: khunt@nova-eye.com
Nova Eye Medical — Shareholder Meeting (November 2023) on 6ix